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5-year overall cost per patient was €13,900-€17,200 in Hungary, €16,300-€18,300 in
Poland, €8,900-€9,600 in Serbia and €12,500-€15,700 in Slovakia (presented in ranges
due to uncertainty around palliative care). Chemotherapy-associated costs ac-
counted for 59-71% of the total, followed by primary surgical treatment (13-23%)
and palliative care (4-15%). Contribution of drug costs to the overall costs varied
among the countries (in Poland 29%, in Serbia 55% of total costs). CONCLUSIONS:
Given the scarcity of OC cost studies worldwide, these findings may provide a
useful source for clinicians and decision makers in understanding the economic
implications of managing ovarian cancer in Central and Eastern Europe and the
need for innovative therapies.
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OBJECTIVES:Toexaminetheincrementalcostsofchemotherapy-associatedAEsinmBC
METHODS: The PharMetrics Database (2000-2010) was used to identify mBC pa-
tients treated with first- or second-line taxane (paclitaxel or docetaxel) or capecit-
abine-based regimens, with treatment episodes (TEs)30 days. Inverse probability
weighting was used to balance patient characteristics between cohorts with and
without AEs. Incremental costs attributable to AEs were assessed by comparing
costs incurred during TEs with and without AEs and included the following com-
ponents: inpatient, outpatient, emergency room, other medical service, pharmacy
costs, and total health care costs. Sensitivity analyses were conducted to examine
the average monthly costs in patients cohorts stratified by the number and type of
AEs reported during the TEs. RESULTS: 3,222 women (mean age57) received a first-
and/or second-line taxane or capecitabine for mBC. Of the 2,678 1st-line patients, 69.7%
received taxane and 30.3% capecitabine. AEs were commonly seen in patients treated
with first-line taxane (94.6%) and capecitabine (83.7%). On average, the total monthly
incremental cost associated with AEs was 38% higher ($3,547) for taxane and 9% higher
($854) for capecitabine. Inpatient and other drug costs accounted for a majority of the
increasedcosts.Of1,084second-linepatients,66.0%receivedtaxaneand34.0%withcape-
citabine.94.4%ofsecond-linetaxanepatientsand84%ofcapecitabinepatientshadanAE.
The average total monthly incremental cost associated with AEs for taxane was $5,320
and $4,933 for capecitabine (69.5% and 82.9% higher vs. patients without AEs). Differences
in pharmacy costs drove the incremental AE-related costs in taxanes users; inpatient and
outpatient costs accounted for the majority of these costs in capecitabine users. Sensitiv-
ity analyses showed a clear trend of an increasing economic burden with the number of
AEs. CONCLUSIONS: Chemotherapy-related AEs are associated with a substantial
economic burden primarily explained by increased inpatient, outpatient, and
pharmacy costs.
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There is some evidence that the annual number of patients diagnosed with anal
cancer in the UK is increasing. Such a rise could potentially have important health
and economic consequences. OBJECTIVES: To estimate hospital treatment costs
for anal cancer in England, based on data from the HES database, as part of a wider
study investigating the total economic burden of anal cancer in the UK.METHODS:
Inpatient admissions for anal cancer between the years 2006/07 to 2010/11 were
retrospectively analysed. Data was obtained from HES, a database covering English
hospital activity, with inpatient episodes aggregated into spells of care associated
with a specific Healthcare Resource Group (HRG). The HRGs were linked to costs
from the UK National Tariff in order to calculate the average annual and per inpa-
tient payments for treatment of anal cancer, as per the NHS Payment by Results
framework. Where necessary, costs were supplemented by expert opinion and
other published cost estimates. A limited amount of HES data on outpatient con-
sultations was also collected and analysed. RESULTS: In England, the average an-
nual payments for inpatient care associated with anal cancer are estimated to total
£7,754,219 (males  £2,930,360, females  £4,823,859). This translated to a mean
annual cost per inpatient of £4,605 and £5,232 for males and females respectively.
Outpatient costs were lower across both genders with annual payments for outpa-
tient care estimated at £184,479 for males and £286,686 for females. This is likely to
be a significant underestimate due to coverage issues with the HES outpatient
dataset on account of local variation in the sources of funding for certain treat-
ments. Further research into outpatient costs is currently ongoing.CONCLUSIONS:
Despite the significant underestimation of the outpatient costs, these results sug-
gest anal cancer places a significant health and economic burden on the English
NHS.
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OBJECTIVES: To assess the management and associated lifetime costs in MM pa-
tients as from the diagnosis of unresectable metastatic disease until death.
METHODS: A retrospective patient chart review was performed at the Antwerp
University Hospital to obtain data on medical consumption related to the manage-
ment of unresectable metastatic MM (umMM). A complete registry of all MM pa-
tients who visited the hospital between 2007 and May 2012 was compiled. Eligible
for this retrospective chart review were patients with umMM with sufficient data
available and who deceased before May 2012. Data on demographics, disease char-
acteristics and management of umMM were collected. Direct costs were calculated
by multiplying each item of resource use with its unit cost (2012, € ) using the
Belgian public health care payer’s perspective (PHCP) and patient’s perspective.
Average (bootstrap 95%CI) overall costs per patient were calculated. RESULTS: Out
of 148 registered MM patients, 29 were eligible and included in this chart review.
The median overall survival time in all patients was 6.0 months. 86% (n25) of
patients were treated by systemic treatment(s) of which 24% (n6) received up to 4
different treatment lines. Dacarbazine was administered in all patients as a single
agent or in combination therapy. 4 patients received 1 to 4 cycles of ipilimumab
treatment. 53 (43%) of the 123 hospitalizations were for chemotherapy administra-
tion. The mean overall cost per patient was €31,637 (bootstrap 95% CI:23,993-
39,891), of which € 30,585 € (95%CI: 23,154-38,784) was reimbursed. The PHCP cost
was driven by hospitalization costs and systemic treatments costs both represent-
ing 33% of total cost. CONCLUSIONS:Management of umMM result in considerable
costs for the PHCP mainly driven by systemic treatment costs and hospitalization
costs. It would be interesting to extend this study in a broader population.
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OBJECTIVES: This review was conducted to assess the economic burden of pancre-
atic cancer (PC) in Europe. METHODS: Systematic search of Embase® and MED-
LINE® databases was conducted from January 2002 to June 2012 to identify eco-
nomic studies on PC in Europe. English language studies, regardless of design and
intervention were included. Eligibility of trials was assessed by two reviewers with
any discrepancy reconciled by a third, independent reviewer. RESULTS: Of the 97
retrieved citations, seven met pre-defined inclusion criteria. Four studies were
cost-analyses while other three were cost-minimisation, cost-utility, and cost-ben-
efit analysis, respectively. In Europe, the predicted PC mortality varied between
6.6-8.2/100,000 men and between 4-5.7/100,000 women in 2012. In Sweden, the
direct costs/patient/month associated with PC rose from €1578 in 2001 to €3103 in
2002-2005 and then to €6590 in 2009. In 2009, the major contributors of this direct
cost were hospitalisations (€4670), surgery (€719), and chemotherapy (€258). The
mean total cost of illness/patient for PC in Germany was €31,375 (cost years 2000-
2003), where direct cost was responsible for 90% of this total value and the remain-
ing 10% was contributed by indirect costs including loss of productivity due to
days-off work. In 2009, the estimated cost/patient associated with loss of produc-
tivity due to absenteeism was €6077 in Sweden. Upon assessment of curative re-
section cost for PC per patient in Sweden, it was found to be about €39,000 in 2009.
The mean costs per patient associated with the use of diagnosis of PC were $1925 in
Switzerland (2004), $1249 in Spain (2001), and €1545 in Sweden (2001).
CONCLUSIONS: Although limited data is available, a trend in increase of fiscal
burden of PC was observed. The major contributors of this burden were surgery,
hospitalisations, chemotherapy, and loss of productivity. Therapies that prevent or
delay disease progression could reduce this burden.
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OBJECTIVES: Chronic lymphocytic leukemia (CLL) is a slowly progressing but mor-
tal disease that imposes a high economic burden on sickness funds and society.
The objective of this study is to analyze and compare the direct and indirect costs
of CLL in Germany from the perspective of both sickness funds and society, and to
analyze the burden of the disease. METHODS: Using a database of 7.6 million
enrolled individuals, we identified 4198 CLL patients in 2007 and 2008. Costs attrib-
utable to CLL were estimated using a case-control design, with a control group of
150 individuals randomly drawn by age and sex for each CLL observation. We used
GEE and count data models to test for differences in costs and health care
utilization. RESULTS: The cost attributable to CLL per prevalent case amounts to
€4946 from the payer’s perspective, and €7910 from that of society. Inpatient stays
and pharmaceutical consumption are the main cost drivers of the disease. The
burden of disease in Germany is estimated to be approximately €201 million per
year from the sickness fund perspective (€322 million from the societal
perspective). CONCLUSIONS: Compared with common diseases such as diabetes
or COPD, the economic burden of CLL is considerably lower. However, the cost of
treatment per case is about twice as high as for these common diseases, even
though treatment is performed in later stages only. Owing to new health care
technologies, an ageing population, and an increasing incidence, it is likely that the
burden of the disease will continue to grow.
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